HC Wainwright Reiterates “Buy” Rating for ANI Pharmaceuticals (NASDAQ:ANIP)

HC Wainwright reissued their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a $94.00 target price on the specialty pharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the stock. Raymond James increased their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Piper Sandler began coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Finally, Truist Financial upped their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.33.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $58.91 on Monday. The stock has a market cap of $1.24 billion, a P/E ratio of -107.11 and a beta of 0.71. ANI Pharmaceuticals has a twelve month low of $48.20 and a twelve month high of $70.81. The stock has a 50 day moving average of $58.48 and a two-hundred day moving average of $61.41. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.05 EPS. On average, research analysts forecast that ANI Pharmaceuticals will post 3.5 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Innealta Capital LLC purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $65,000. Ridgewood Investments LLC purchased a new position in ANI Pharmaceuticals during the second quarter worth approximately $85,000. SG Americas Securities LLC acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at $106,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth $207,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.